Metastatic gastrointestinal stromal tumor (GIST) harbouring a KIT exon 9 mutation is a molecularly defined subgroup with specific treatment implications. Management in this population requires attention to mutation status when selecting and sequencing therapy.
This protocol addresses metastatic GIST with a confirmed KIT exon 9 mutation. Evidence-based guidance distinguishes this subtype from other mutation profiles, with dedicated recommendations for appropriate agent selection at each line of therapy.
Third-line systemic therapy with a targeted agent is recommended in this setting. The appropriate agent, along with its administration schedule and decision criteria, is defined in the full structured regimen.
DOI: 10.1177/17588359231192388